You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨康方生物(09926.HK)逆勢漲近3% 多個自主研發藥物完成入組及給藥
格隆匯 06-18 10:38
格隆匯6月18日丨次新股康方生物(09926.HK)逆勢漲近3%,報31.4港元,股價刷新上市以來新高,總市值247億港元。康方生物於4月24日以招股價16.18港元上市。本月以來,公司自主研發創新藥AK111(IL-17A單克隆抗體)在中國1b期臨牀試驗中,首例中重度斑塊狀銀屑病患者已經順利完成入組及給藥。公司自主研發的VEGFR-2新型全人源化單克隆抗體藥物AK109在中國劑量爬坡I期臨牀試驗中,首例晚期實體瘤患者已經順利完成入組及給藥。公司自主研發的IL-4R單克隆抗體注射液AK120在新西蘭臨牀I期試驗中,首例健康受試者已經順利完成入組及給藥。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account